Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Autores principales: van Andel, Lotte, Zhang, Z., Lu, S., Kansra, V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., Beijnen, J. H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694528/
https://ncbi.nlm.nih.gov/pubmed/28303528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0451-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares